

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

Jacques DEGELAEN et al. :


Docket No. 00292/16.72.37

Serial No. 09/276,923 :

Group Art Unit 1645

Filed March 26, 1999 :

Examiner L. Lee



PROCESS FOR DETERMINING
ANTIBIOTICS CONTAINING A
 β -LACTAM RING IN A BIOLOGICAL FLUID

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of (X) the references listed on the attached Form PTO-1449 and/or () the additional information identified below in paragraph 4. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. .

1. This Information Disclosure Statement is submitted:

a. ☐ within 3 months of the filing date of the above-identified application, or
☐ within 3 months of entry into National stage prosecution of an International application, or ☐ before the mailing date of the first Office Action on the merits, and thus:

☐ no certification and/or fee is required.

b. ☒ after the events of above paragraph 1a and prior to the mailing date of a final Office Action or Notice of Allowance, and thus:

☐ the certification of paragraph 2 below is provided,
or

08/24/2000 HCHRISTA 00000031 09276923

01 FC:126

240.00 DP


- (X) a fee of \$240.00 is enclosed.
- c. () after the mailing date of a final Office Action or a Notice of Allowance and prior to payment of the issue fee, and thus:
- () the certification of paragraph 2 below is provided,
and
- () the Petition of paragraph 3 below is provided and \$130.00 fee therefor is enclosed.
2. It is hereby certified
- () that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- () that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3. () Petition under 37 CFR 1.97 for consideration of this Information Disclosure Statement is hereby made.
4. () Consideration of the following additional information (including any co-pending or abandoned U.S. application, prior uses and/or sales, etc.) is requested:
5. () For each non-English language reference listed on the attached Form PTO-1449:
- () reference is made to an English language translation or abstract submitted herewith, and/or

- () reference is made to a foreign patent office search report (in the English language) submitted herewith, and/or
 - () reference is made to an English language translation of a foreign patent office search report submitted herewith, and/or
 - () reference is made to the concise explanation contained in the specification of the present application at page(s) , and/or
 - () reference is made to the concise explanation set forth below:
6. () Applicant also offers the following comments for the Examiner's consideration:
7. () Also enclosed is a copy of the European Search Report citing these references.

Respectfully submitted,

Jacques DEGELAEN et al.

By



Ralph H. Dean, Jr.
Registration No. 41,550
Attorney for Applicants

RHD/jlw
Washington, D.C.
Telephone (202) 721-8200
August 23, 2000

RECEIVED

AUG 29

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Jacques DEGELAEN et al.

Serial No. 09/276,923

Filed March 26, 1999



:
: Atty Docket 00292/16.72.37
: Group Art Unit 1645
: Examiner L. Lee

PROCESS FOR DETERMINING ANTIBIOTICS
CONTAINING A B-LACTAM RING IN A
BIOLOGICAL FLUID

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$240.00 to cover Patent Office fees relating to filing the following attached papers:

Information Disclosure Statement \$240.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Jacques DEGELAEN et al.

By

Ralph H. Dean, Jr.
Registration No. 41,550
Attorney for Applicants

RHD/jlw
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006
Telephone (202) 721-8200
August 23, 2000

[Check No. 39455]

99_0318A